CD_NAME : CD2

    DESC: CD2 antigen (p50); sheep red blood cell receptor
    LT2 IgG2b  Filatov  AbD Serotec
    RPA-2.10 IgG1k  Aversa  BD Biosciences
    RPA-2.10 IgG1k  Aversa  BioLegend
    RPA-2.10 IgG1k  Aversa  AbD Serotec
    RPA-2.10 IgG1k  Aversa  Thermo Fisher Scientific
    TS1/8 BioLegend
    TS1/8 Mouse IgG1 kappa EXBIO Praha
    LT2 Mouse IgG2b Filatov EXBIO Praha
    MEM-65 Mouse IgG1 Horejsi EXBIO Praha
    1E7E8 IgG2a  Fox 
    1MONO2A6 IgG3  Reinherz 
    6F10.3 IgG1  Mawas 
    7A9 IgM  Reinherz 
    37994 IgG2b Naito
    38025 IgM Naito
    9.6 IgG2a Kamoun MM
    35.1 IgG2a Martin PJ
    39B21 IgG2a  Mawas 
    39C1.5 IgG2a  Mawas 
    39C8.18 unknown  Mawas 
    39H7.3 unknown  Mawas 
    41F2.1 unknown  Mawas 
    95-5-49 unknown  Quinones 
    AICD2.1 IgG2a  Meuer 
    B-E2 IgG2b  Wijdenes 
    CD2X11 IgG1  Boumsell 
    CLB-T11.1/1 IgG1  van Lier 
    CLB-T11/1 IgG1  Tetteroo 
    CLB-T11.2/1 IgG1  van Lier 
    CTAG-CD2, G11 IgG1  Johnson 
    D66/1 IgG2b  Bernard 
    D66 (??) IgM  Bernard 
    D66 clone1 (??) IgM  Bernard 
    F92-3A11 (S-T21) IgG1  Poncelet 
    F110.08 IgG1  Plesner 
    GT2 IgG1  Bernard 
    HIT11 IgG1  Chen 
    JN-20-5 unknown  Bai 
    JOR-T2 IgG2b  Amador 
    L303 IgG2a  Maino 
    Leu-5b IgG2ak  Warner 
    Leu-5D IgG1  Becton Dickinson 
    LT2 IgG2b  Filatov  AbD Serotec
    M-T26 IgG1  Rieber 
    M-T110 unknown  Rieber 
    M-T201 IgG1  Rieber 
    M-T910 IgG1  Rieber 
    M-T1110 IgG1  Rieber 
    MEM-65 IgG1  Horejsi 
    NU-T1 IgG1  Sagawa 
    NU-TER IgG1  Yokoyama 
    O275 IgG1  Bernard 
    OCH.217 IgM  Colombani 
    OKT11 IgG2a  Ortho 
    OR 101 IgG1  Gazit 
    RPA-2.10 IgG1k  Aversa  BD Biosciences
    SA1-11 IgG1  Yang 
    T11 IgG1  Coulter 
    T11 /3PT2H9 IgG1  Meuer SC 
    T11 /3T4-8B5 IgG2a  Reinherz 
    T11 /7E10 IgG2b  Reinherz 
    T11 /7T4-7A9 IgM  Reinherz 
    T11 /7T4-7E10 IgG2b  Reinherz 
    T11 /7T47E10 IgG2b  Reinherz 
    T11 /ROLD2-1H8 IgG1  Reinherz 
    T56 IgM  Maeda 
    T57 IgG  Maeda 
    T411B5 IgG ??  Girardet 
    TS1/8.1.1 IgG1  Springer 
    TS2/18.1.1 IgG1  Springer 
    WuT11-1 IgG1  Bin 
    X/3 unknown  Pulford 
    XIX.8 IgG2b  Bourel 
    RPA-2.10 IgG1k  Aversa  BioLegend
    RPA-2.10 IgG1k  Aversa  AbD Serotec
    RPA-2.10 IgG1k  Aversa  Thermo Fisher Scientific
    TS1/8 BioLegend
    TS1/8 Mouse IgG1 kappa EXBIO Praha
    LT2 Mouse IgG2b Filatov EXBIO Praha
    MEM-65 Mouse IgG1 Horejsi EXBIO Praha

    CD2 is a type 1 protein with two immunoglobulin superfamily (IgSF) domains. The N-terminal domain is the ligand binding domain.1 It has five proline-rich stretches in its cytoplasmic tail involved in signal transduction.2-4

    1. Gray F, Cyster JG, Willis AC, Barclay AN, Williams AF. Structural analysis of the CD2 T lymphocyte antigen by site-directed mutagenesis to introduce a disulphide bond into domain 1. Protein Eng. 1993;6:965-70.
    2. Bell GM, Fargnoli J, Bolen JB, Kish L, Imboden JB. The SH3 domain of p56lck binds to proline-rich sequences in the cytoplasmic domain of CD2. J Exp Med. 1996;183:169-78.
    3. King PD, Sadra A, Teng JM, Bell GM, Dupont B. CD2-mediated activation of the Tec-family tyrosine kinase ITK is controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail. Int Immunol. 1998;10:1009-16.
    4. Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, Widder P, Rosenberger F, van der Merwe PA, Allen PM, Shaw AS. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell.1998;94:667-77.

    CD58 in humans.1,2 CD48 in rodents.3-5

    Intracellular associate molecules
    Fyn, Lck, CD2AP, CD2BP1 and CD2BP2.6-9

    1. Ikemizu S, Sparks LM, van der Merwe PA, Harlos K, Stuart DI, Jones EY, Davis SJ. Crystal structure of the CD2-binding domain of CD58 (lymphocyte function-associated antigen 3) at 1.8-A resolution. Proc Natl Acad Sci U S A. 1999;96:4289-94.
    2. Wang JH, Smolyar A, Tan K, Liu JH, Kim M, Sun ZY, Wagner G, Reinherz EL. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell. 1999;97:791-803.
    3. Kato K, Koyanagi M, Okada H, Takanashi T, Wong YW, Williams AF, Okumura K, Yagita H. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J Exp Med. 1992;176(5):1241-9.
    4. Davis SJ, Ikemizu S, Wild MK, van der Merwe PA. CD2 and the nature of protein interactions mediating cell-cell recognition. Immunol Rev. 1998;163:217-36.
    5. Zhu B, Davies EA, van der Merwe PA, Calvert T, Leckband DE. Direct measurements of heterotypic adhesion between the cell surface proteins CD2 and CD48. Biochemistry. 2002;41:12163-70.
    6. Carmo AM, Mason DW, Beyers AD. Physical association of the cytoplasmic domain of CD2 with the tyrosine kinases p56lck and p59fyn. Eur J Immunol. 1993;23:2196-201.
    7. Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, Widder P, Rosenberger F, van der Merwe PA, Allen PM, Shaw AS. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998;94:667-77.
    8. Freund C, Kühne R, Yang H, Park S, Reinherz EL, Wagner G. Dynamic interaction of CD2 with the GYF and the SH3 domain of compartmentalized effector molecules. EMBO J. 2002;21:5985-95.
    9. Yang H, Reinherz EL. CD2BP1 modulates CD2-dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)-PEST. J Immunol. 2006;176:5898-907.


    CD_NAME : CD2

    It is expressed at high density on thymocytes, T-cells and on NK cells. It is one of the earliest markers expressed in T-cell development. CD2 is also expressed on mast cells, a subset of thymic B cells and dendritic cells.1-3

    1. Hauswirth AW, Florian S, Schernthaner GH, Krauth MT, Sonneck K, Sperr WR, Valent P. Expression of cell surface antigens on mast cells: mast cell phenotyping. Methods Mol Biol. 2006;315:77-90.
    2. Punnonen J, de Vries JE. Characterization of a novel CD2+ human thymic B cell subset. J Immunol. 1993;151:100-10.
    3. Crawford K, Stark A, Kitchens B, Sternheim K, Pantazopoulos V, Triantafellow E, Wang Z, Vasir B, Larsen CE, Gabuzda D, Reinherz E, Alper CA. CD2 engagement induces dendritic cell activation: implications for immune surveillance and T-cell activation. Blood. 2003;102:1745-52.


    CD_NAME : CD2

    CD2 functions as an adhesion, between T cells and antigen-presenting cells or NK cells and target cells, and costimulatory molecule. CD2 is not essential for the development and function of T cells.1 It has been shown to regulate TCR-affinity thresholds for T cell activation.2
    CD2 colocalize with TCR in the center of the immne synapse, recruiting and activating several intracellular molecules, increasing T and NK cell signaling and cytotoxicity.3-5

    1. Killeen N, Stuart SG, Littman DR. Development and function of T cells in mice with a disrupted CD2 gene. EMBO J. 1992;11:4329-36.
    2. van der Merwe PA. A subtle role for CD2 in T cell antigen recognition. J Exp Med. 1999;190:1371-4.
    3. Singleton K, Parvaze N, Dama KR, Chen KS, Jennings P, Purtic B, Sjaastad MD, Gilpin C, Davis MM, Wülfing C. A large T cell invagination with CD2 enrichment resets receptor engagement in the immunological synapse. J Immunol. 2006;177:4402-13.
    4. Espagnolle N, Depoil D, Zaru R, Demeur C, Champagne E, Guiraud M, Valitutti S. CD2 and TCR synergize for the activation of phospholipase Cgamma1/calcium pathway at the immunological synapse. Int Immunol. 2007;19:239-48.
    5. Kaizuka Y, Douglass AD, Vardhana S, Dustin ML, Vale RD. The coreceptor CD2 uses plasma membrane microdomains to transduce signals in T cells. J Cell Biol. 2009;185:521-34.
    6. Leitner J, Herndler-Brandstetter D, Zlabinger GJ, Grubeck-Loebenstein B, Steinberger P. CD58/CD2 Is the Primary Costimulatory Pathway in Human CD28-CD8+ T Cells. J Immunol. 2015;195:477-87.


    CD_NAME : CD2

    Cell marker

    Useful as a T and NK cell marker.
    Phenotypic typing and NK cell and T leukemias and lymphomas.1-3 CD2 is expressed on neoplastic mast cells.4 Myeloma cells also express significant levels of CD2.5


    Siplizumab (MEDI-507) is humanized monoclonal antibody against CD2 molecule that has been studied for the treatment of severe psoriasis and for prophylaxis of GvHD because of its T-cell depleting properties.6-8 Phase I/II trial of slipizumab in patients with malignant T-cell lymphoproliferative disorders have been initiated.9

    Alefacept (Amevive) is a CD58-immunoglobulin (Ig) Fc fusion protein that binds to CD2. It has been approved for the treatment of psoriasis.10 Recently, it has been tested for the treatment of insulin-dependent diabetes.11

    1. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19:2186-94.
    2. Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2011;79:330-43.
    3. Ohshima K. Molecular Pathology of Adult T-Cell Leukemia/Lymphoma. Oncology. 2015;89 Suppl 1:7-15.
    4. Escribano L, Díaz-Agustín B, Núñez R, Prados A, Rodríguez R, Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol. 2002;127:127-32.
    5. Ruiz-Argüelles GJ, San Miguel JF. Cell surface markers in multiple myeloma. Mayo Clin Proc. 1994;69:684-90.
    6. Bissonnette R, Langley RG, Papp K, Matheson R, Toth D, Hultquist M, Geba GP, White B. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Arch Dermatol Res. 2009;301:429-42.
    7. Langley RG, Papp K, Bissonnette R, Toth D, Matheson R, Hultquist M, White B. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. Int J Dermatol. 2010;49:818-28.
    8. Brochstein JA, Grupp S, Yang H, Pillemer SR, Geba GP. Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease. Pediatr Transplant. 2010;14:233-41.
    9. O'Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, Pittaluga S, Raffeld M, Albert PS, Reitsma D, Kaucic K, Hammershaimb L, Waldmann TA, Janik JE. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res. 2009;15:2514-22.
    10. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005;102:2075-80.
    11. Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125:3285-96.


    CD_NAME : CD2


    DESC CD2 antigen (p50); sheep red blood cell receptor


    HGNC_LOCUS_TAG: 1639
    NCBI_MAP: 1p13
    GENE_SIZE: 14750
    PRCORENC: 14 to 1069
    ENTREN: ENST00000369478
    NCBI_REF_SEF_ENTRY: NP_001758 , 4502653
    PR_MO_WEIGHT: 39439
    PR_SW_PR: 10.00
    IPI_NUMBER: IPI00027484
    ENSM_NUMBER: P06729

HCDM Sponsors: